Loading clinical trials...
Loading clinical trials...
An Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Neoral® in Cardiac Transplant Recipients With Established Allograft Vasculopathy
Conditions
Interventions
everolimus
Locations
6
United States
UCLA Medical Center
Los Angeles, California, United States
University of Minnesota, Fairfield University Hospital
Minneapolis, Minnesota, United States
Columbia Presbyterian Medical Center
New York, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
Midstate Cardiology
Nashville, Tennessee, United States
Start Date
August 1, 2004
Primary Completion Date
April 1, 2005
Last Updated
July 12, 2010
NCT00106925
NCT06532890
NCT07316829
NCT03719339
NCT06090799
NCT02102854
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions